Device Trial Radar · NCT07766187
Combination Therapy Using Durvalumab and Histotripsy for Treatment of Intrahepatic Cholangiocarcinoma
Last checked: Nov 20, 2026Latest source record: Oct 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
12
Planned (sponsor's estimate)
Start
Nov 2026
Primary completion
Aug 2032
Study completion Aug 2032
Sponsor
- Lead sponsor
- University of Wisconsin, MadisonAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- HistoSonics, Inc.
- First posted
- Aug 14, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this research is to evaluate whether adding histotripsy to maintenance durvalumab increases immune response and to assess the safety of this combination for participants with advanced intrahepatic cholangiocarcinoma (iCCA). Histotripsy is a non-invasive, non-thermal treatment that uses focused ultrasound energy to destroy tumor tissue. 12 people will be enrolled in this study.
Conditions
- Intrahepatic Cholangiocarcinoma
Interventions
HistotripsyDevice
Histotripsy will be performed using the Edison® System (HistoSonics, Inc.), which is FDA cleared for destruction of liver tissue using non thermal focused ultrasound. Performed on Cycle 1 Day 8 (C1D8) to treat the Target Tumor.
DurvalumabDrug
Durvalumab is an immunotherapy drug and will be administered on day 1 of each 28-day cycle as per local standards. Dosing of maintenance durvalumab is 1500mg IV per FDA labeling with administration performed over 60 minutes as per standard clinical practice.
BiopsyProcedure
Two research biopsies are planned for cycle 1 day 3 and cycle 1 day 22, before and after histotripsy.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants with Increase in Adaptive Immune System Response following histotripsyTime frame: data collected cycle 1 day 3 (C1D3) and cycle 1 day 22 (C1D22) (up to about 30 days with allowable procedural windows)
- Percent of Participants Experiencing Immune-mediated Adverse Events within 30 days of histotrispyTime frame: data collected up to day 38 (30 days post-histotripsy)
Locations
1 site in 1 country. Site status is shown where the registry gives one.
University of Wisconsin
Madison, Wisconsin · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.